Shooting Cancer

12 04, 2022

ALK rearrangements: a biomarker at the forefront of NSCLC treatment

Diatech Pharmacogenetics2022-04-12T12:18:29+02:00

17 03, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022

Diatech Pharmacogenetics2022-03-17T17:35:47+01:00

23 02, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- January 2022

Diatech Pharmacogenetics2022-04-12T17:30:48+02:00

26 01, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- December 2021

Diatech Pharmacogenetics2022-01-27T17:31:38+01:00

21 12, 2021

Shooting Cancer – Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November 2021

Diatech Pharmacogenetics2021-12-21T17:19:16+01:00

9 11, 2021

NTRK inhibitors, a successful example of a tissue-agnostic approach in anticancer targeted therapy

Diatech Pharmacogenetics2021-11-09T17:01:50+01:00

22 09, 2021

KRAS, a new weapon for the fight against lung cancer and more

Diatech Pharmacogenetics2021-09-22T11:58:07+02:00

30 06, 2021

Lung cancer: molecular markers and new opportunities to treat the early and advanced disease

Diatech Pharmacogenetics2021-07-02T13:53:43+02:00

31 05, 2021

Utility and use of NGS in clinical oncology: ESMO recommendations for patients with metastatic cancers

Diatech Pharmacogenetics2021-05-31T15:56:48+02:00

2 04, 2021

Europe approves the first anti-PD-L1/L1 therapy for patients with MSI-H/dMMR colorectal cancer

Diatech Pharmacogenetics2021-04-02T16:14:30+02:00

Vorheriges 234 Nächstes